Aktis Oncology, Inc. (AKTS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.50: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein... Read more
Sell if holding. Engine safety override at $18.50: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.9/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 86d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Aktis Oncology, Inc.
Latest news
- Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate — benzinga May 11, 2026 positive
- Aktis Oncology Starts Phase 1b Clinical Study Of AKY-25191 In Participants With Metastatic Castration-resistant Prostate — benzinga May 4, 2026 positive
- This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday — benzinga Apr 29, 2026 positive
- William Blair Initiates Coverage On Aktis Oncology with Outperform Rating — benzinga Apr 29, 2026 positive
- TAktis Oncology To Present First Clinical Imaging And Dosimetry Data For AKY-2519 At the 2026 American Society of Clinic — benzinga Apr 21, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·2 ceiling hits
Volatile — 6.4% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.50: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $17.34. Score 5.9/10, moderate confidence.
Take-profit target: $28.19 (+52.4% upside). Prior stop was $17.34. Stop-loss: $17.34.
Quality below floor (2.9 < 4.0).
Aktis Oncology, Inc. trades at a P/E of N/A (forward -9.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts cover AKTS with a consensus score of 4.3/5. Average price target: $32.
What does Aktis Oncology, Inc. do?Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of...
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.